Kera Capital Partners Inc. Buys Shares of 23,052 iShares Biotechnology ETF $IBB

Kera Capital Partners Inc. bought a new position in iShares Biotechnology ETF (NASDAQ:IBB) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 23,052 shares of the financial services provider’s stock, valued at approximately $3,975,000.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Citigroup Inc. raised its stake in iShares Biotechnology ETF by 40.9% during the 4th quarter. Citigroup Inc. now owns 5,242,688 shares of the financial services provider’s stock worth $884,808,000 after buying an additional 1,521,992 shares during the period. BNP Paribas Financial Markets grew its stake in iShares Biotechnology ETF by 313.2% in the third quarter. BNP Paribas Financial Markets now owns 1,915,395 shares of the financial services provider’s stock valued at $276,526,000 after acquiring an additional 1,451,820 shares during the period. Raymond James Financial Inc. grew its stake in iShares Biotechnology ETF by 286.2% in the fourth quarter. Raymond James Financial Inc. now owns 994,311 shares of the financial services provider’s stock valued at $167,810,000 after acquiring an additional 736,881 shares during the period. WestEnd Advisors LLC bought a new stake in shares of iShares Biotechnology ETF in the fourth quarter worth about $106,276,000. Finally, Truist Financial Corp increased its holdings in shares of iShares Biotechnology ETF by 2,239.6% in the fourth quarter. Truist Financial Corp now owns 642,023 shares of the financial services provider’s stock worth $108,354,000 after acquiring an additional 614,582 shares in the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Up 0.1%

NASDAQ IBB opened at $173.64 on Friday. The stock’s 50-day moving average is $170.57 and its 200-day moving average is $170.64. iShares Biotechnology ETF has a one year low of $123.61 and a one year high of $179.64.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were paid a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a yield of 0.1%. The ex-dividend date of this dividend was Monday, June 15th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.